Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Norris Medicines has informed that it enclosed Standalone Un-audited Financial Results of the Company for the Quarter ended on 30th September, 2022; Limited Review Report on Standalone Un-audited Financial Results for the quarter ended on 30th September, 2022.
The above information is a part of company’s filings submitted to BSE.